PediatricsResuscitation Algorithm

Pediatric Status Epilepticus

Pediatric seizure management pathway with medication sequencing and escalation checkpoints.

Query: How do I manage pediatric status epilepticus?

Summary

For children >1 month old with status epilepticus (i.e. seizure >5 minutes or recurrent seizures without full recovery), begin with supportive care (airway, breathing, circulation, rapid blood glucose check) then immediately initiate first‐line benzodiazepine therapy. Escalate to second‐line anti‐epileptics if seizures persist despite 2 doses.

Agents
  • Dose: If IV/IO access is available, give Lorazepam 0.1 mg/kg (max 4 mg) as a slow push; alternatively, if access is lacking, use Midazolam 0.2 mg/kg IM/intranasally (max 10 mg/dose)
  • When: Should be administered as soon as the seizure lasts >5 minutes, with a repeat dose if seizures persist after 3 minutes
  • Monitoring: Continuous cardiorespiratory monitoring (pulse oximetry, end-tidal CO₂ if available) and frequent neurologic assessments
Caution
  • Excessive dosing of benzodiazepines can lead to respiratory depression and require airway intervention^1
  • In toxin-induced seizures (e.g., cocaine toxicity), avoid agents like fosphenytoin that block sodium channels^3
  • Hemodynamic instability may occur with second-line agents (e.g., fosphenytoin), so monitor blood pressure closely
Targets
  • Goal: Terminate seizure activity promptly to minimize neuronal injury and multi-organ effects
  • Hold/stop if: Seizure activity ceases and the patient returns to baseline with maintained airway and stable hemodynamics

Dosing

PopulationDoseMaxNotes
Pediatric (Benzodiazepines)Lorazepam 0.1 mg/kg IV/IO; OR Midazolam 0.2 mg/kg IM/INLorazepam: 4 mg; Midazolam: 10 mgFirst dose; may administer one repeat dose if seizures persist
Pediatric (Second-line options)Levetiracetam 60 mg/kg IV/IO4500 mgInfuse over 5 minutes; preferred given rapid administration and favorable side effect profile ^1 ^4
Fosphenytoin 20 mg PE/kg IV/IO1500 mgInfuse over 10 minutes; avoid in toxin-induced seizures
Valproate 40 mg/kg IV/IO3000 mgInfuse over 10 minutes; use cautiously in patients with liver dysfunction
Phenobarbital 20 mg/kg IV/IO1000 mgInfuse over 20 minutes; watch for respiratory depression (especially when combined with benzos)

Adjustments

  • Renal: Consider dose adjustments for Levetiracetam in renal impairment.
  • Hepatic: Use caution with Valproate in patients with hepatic dysfunction.
  • Obesity: Dosing remains weight-based; in obese patients, careful weight measurement is important for accurate dosing.

Adverse effects to watch for

  • Respiratory depression (especially with benzodiazepines and phenobarbital)
  • Hypotension during infusions of fosphenytoin or valproate
  • Excessive sedation, which may necessitate airway protection

Alternatives

  • If benzodiazepine first-line therapy fails and IV access delays second-line treatment, intranasal midazolam is an effective alternative.
  • Levetiracetam is favored as second-line therapy due to its rapid administration and lower drug–drug interaction potential.
  • If contraindications exist (e.g., liver dysfunction with valproate or toxin-induced seizures for fosphenytoin), adjust the choice of second-line agent accordingly ^1 ^5

^1 ^3 ^4 ^5

References